Insurers Are Charging Thousands of Dollars for Generic Drugs
The cancer drug Gleevec went generic in 2016 and can be bought today for as little as $55 a month. But many patients’ insurance plans are paying more than 100 times that. (Source: Reuters: Health)
Source: Reuters: Health - September 11, 2023 Category: Consumer Health News Source Type: news

Targeted Agents Go Head-to-Head for Newly Diagnosed Ph+ ALL
(MedPage Today) -- In the first randomized comparison of targeted agents for acute lymphoblastic leukemia (ALL), ponatinib (Iclusig) prevailed over imatinib for untreated Philadelphia chromosome-positive (Ph+) cases. More than twice as many patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2023 Category: Hematology Source Type: news

Analysis of ctDNA Pinpoints Responders to Second-Line GIST Therapy
(MedPage Today) -- Circulating tumor DNA (ctDNA) analysis of KIT mutational status may be able to guide second-line treatment in patients with imatinib-resistant gastrointestinal stromal tumors (GIST), according to an exploratory analysis from... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 28, 2023 Category: Gastroenterology Source Type: news

Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
BOSTON and ATLANTA, Aug. 26, 2022 -- (Healthcare Sales & Marketing Network) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parki... Biopharmaceuticals, Oncology, FDA Inhibikase Therapeutics, imatinib , Chronic Myelogenous Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2022 Category: Pharmaceuticals Source Type: news

Many Online Pharmacies Sell Imatinib Without Prescription
TUESDAY, Aug. 2, 2022 -- Many online pharmacies sell imatinib without requiring a prescription, and nearly one-quarter do not include warnings related to imatinib, according to a study published in the July issue of the Journal of the National... (Source: - Pharma News)
Source: - Pharma News - August 2, 2022 Category: Pharmaceuticals Source Type: news

'Rogue' Online Pharmacies Are Dispensing Cancer Drugs
(MedPage Today) -- Dozens of illegitimate online pharmacies are selling imatinib, an oral chemotherapy drug for chronic myeloid leukemia (CML), putting patients at risk for toxicities and treatment failures, researchers found. Of 44 online pharmacies... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 29, 2022 Category: American Health Source Type: news

Mark Cuban Pharmacy Offers Imatinib at a Fraction of the Cost Mark Cuban Pharmacy Offers Imatinib at a Fraction of the Cost
Mark Cuban has launched a discount pharmacy offering generic drugs at a substantially lower cost than current retail pricing, and currently has several cancer drugs in the formulary.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 18, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Alembic gets USFDA nod for cancer treatment drug
Dasatinib Tablet is indicated for the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 10, 2022 Category: Pharmaceuticals Source Type: news

Cancer drug may treat severe COVID-19, study finds
Patients with severe COVID-19 who received the cancer drug imatinib were less likely to die than those not treated with it. (Source: Health News -
Source: Health News - - May 18, 2022 Category: Consumer Health News Source Type: news

Information on Gleevec (Imatinib Mesylate)
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 7, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Seven countries in the Region to participate in WHO ’s Solidarity PLUS trial
WHO’s Solidarity PLUS trial enters new phase to test 3 new candidate drugs for COVID-19  Cairo, 25 August 2021 – Seven countries in WHO’s Eastern Mediterranean Region have enrolled to participate in the Solidarity PLUS clinical trial led by WHO. Solidarity PLUS will evaluate 3 potential drugs for the treatment of COVID-19 infections – artesunate, imatinib and infliximab – aiming to protect people from severe hospitalization and death because of COVID-19.  These drugs were selected by an independent panel of experts who assess all available evidence on all relevant therapeutics. The drugs have proven...
Source: WHO EMRO News - August 25, 2021 Category: Middle East Health Source Type: news

WHO-led trial is studying three anti-inflammatory drugs as potential COVID-19 treatments 
A trial led by the World Health Organization is testing three anti-inflammatory drugs - artesunate, imatinib and infliximab- as potential treatments for COVID-19. (Source: the Mail online | Health)
Source: the Mail online | Health - August 12, 2021 Category: Consumer Health News Source Type: news

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial, The Lancet Respiratory Medicine
In this RCT (n=400), imatinib (800mg load followed by 400mg daily on days 1-9) did not reduce the time to discontinuation of ventilation and supplemental oxygen for more than 48 consecutive hours in patients with COVID-19 requiring supplemental oxygen. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 21, 2021 Category: Consumer Health News Source Type: news

Specialty Generics Face A Maze Of Perverse Incentives In Medicare Part D
Specialty generics haven't gained the kind of traction in Medicare Part D that one would expect. This includes specialty generics such as imatinib mesylate and glatiramer acetate. The current set-up of the Medicare Part D benefit sends the wrong price signals. (Source: Healthcare News)
Source: Healthcare News - January 4, 2021 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news

Conformational states dynamically populated by a kinase determine its function
Protein kinases intrinsically sample a number of conformational states with distinct catalytic and binding activities. We used nuclear magnetic resonance spectroscopy to describe in atomic-level detail how Abl kinase interconverts between an active and two discrete inactive structures. Extensive differences in key structural elements between the conformational states give rise to multiple intrinsic regulatory mechanisms. The findings explain how oncogenic mutants can counteract inhibitory mechanisms to constitutively activate the kinase. Energetic dissection revealed the contributions of the activation loop, the Asp-Phe-Gl...
Source: ScienceNOW - October 8, 2020 Category: Science Authors: Xie, T., Saleh, T., Rossi, P., Kalodimos, C. G. Tags: Biochemistry, Online Only r-articles Source Type: news